NO178175B - Process for preparing a soft gelatin capsule - Google Patents
Process for preparing a soft gelatin capsule Download PDFInfo
- Publication number
- NO178175B NO178175B NO892077A NO892077A NO178175B NO 178175 B NO178175 B NO 178175B NO 892077 A NO892077 A NO 892077A NO 892077 A NO892077 A NO 892077A NO 178175 B NO178175 B NO 178175B
- Authority
- NO
- Norway
- Prior art keywords
- extr
- silicone oil
- substance
- viscosity
- mixture
- Prior art date
Links
- 239000007903 gelatin capsule Substances 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 16
- 239000000126 substance Substances 0.000 claims abstract description 18
- 239000000419 plant extract Substances 0.000 claims abstract description 8
- 229920002545 silicone oil Polymers 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 21
- 239000013543 active substance Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 14
- 239000000725 suspension Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 10
- 241001116389 Aloe Species 0.000 claims description 4
- 235000011399 aloe vera Nutrition 0.000 claims description 4
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 239000002904 solvent Substances 0.000 abstract description 5
- 150000001298 alcohols Chemical class 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229920005862 polyol Polymers 0.000 abstract 1
- 150000003077 polyols Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 10
- 238000005096 rolling process Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- GOZDTZWAMGHLDY-UHFFFAOYSA-L sodium picosulfate Chemical compound [Na+].[Na+].C1=CC(OS(=O)(=O)[O-])=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OS([O-])(=O)=O)C=C1 GOZDTZWAMGHLDY-UHFFFAOYSA-L 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 206010059360 Gastrocardiac syndrome Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000009701 Senna Extract Substances 0.000 description 1
- 229920004482 WACKER® Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012051 hydrophobic carrier Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229960005077 sodium picosulfate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Oppfinnelsen vedrører en fremgangsmåte til fremstilling av en mykgelantinkapsel, som er spesielt beregnet for terapi av mage-tarmområdet, hvor et terapeutisk virksomt stoff sammenblandes. Blandingen kan derved foreligge som emulsjon, suspensjon, dispersjon, løsning eller som blanding. The invention relates to a method for producing a soft gelatin capsule, which is especially intended for therapy of the gastrointestinal tract, where a therapeutically active substance is mixed together. The mixture can therefore be present as an emulsion, suspension, dispersion, solution or as a mixture.
Mykgelantinkapsler egner seg som kjent, som gunstig administrasjonsform for legemidler av mange forskjellige typer da de på fremstillingsteknisk enkel måte kan oppta virksomme stoffer og bærere i ønskede forhold og hurtig kan bringe legemiddelet til virkning. Som eksempel skal det vises til administreringsformen for oppløst ibuprofin ved hjelp av mykgelantinkapsler, idet dette middelet mot smerter etter inntagning blir resorbert særlig hurtig slik at man dermed oppnår en hurtig og pålitelig innledning av virkningen. As is well known, soft gelatin capsules are suitable as a favorable form of administration for medicines of many different types, as they can take up active substances and carriers in desired conditions in a simple manufacturing technique and can quickly bring the medicine into effect. As an example, reference should be made to the form of administration of dissolved ibuprofen using soft gelatin capsules, as this remedy for pain is absorbed particularly quickly after ingestion so that a rapid and reliable onset of action is thus achieved.
Ved fremstillingen av mykgelantinkapsler er det i dag vanlig at de innkapslede virksomme stoffer (virksomme substanser) bringes i en via pumper, doserbar form. Som løsningsmiddel til dette formål utgår vann og lavere alkoholer da de ikke er stabile i kapselen. Foretrukte løsningsmidler er planteoljer, nøytrale oljer og polyethylenglykoler. Substanser som ikke er løselige må bringes i en mest mulig stabil emulsjonsform. Som emulgatorer benyttes polyethylenglykoler, bl.a. lesitiner, planteoljer og bivoks. In the production of soft gelatin capsules, it is common today for the encapsulated active substances (active substances) to be delivered in a form that can be dosed via pumps. Water and lower alcohols are used as solvents for this purpose as they are not stable in the capsule. Preferred solvents are vegetable oils, neutral oils and polyethylene glycols. Substances that are not soluble must be brought into the most stable emulsion form possible. Polyethylene glycols are used as emulsifiers, e.g. lecithins, vegetable oils and beeswax.
Den oppgave som ligger til grunn for oppfinnelsen er å tilveiebringe en fremgangsmåte som gjør det mulig å bringe det virksomme stoff, spesielt en pulverformet substans i en form som kan innkaples direkte sammen med bærersubstansen. The task underlying the invention is to provide a method that makes it possible to bring the active substance, especially a powdered substance, in a form that can be encapsulated directly together with the carrier substance.
Denne oppgave blir løst ifølge oppfinnelsen ved en fremgangsmåte av den innledningsvis nevnte art, som er kjennetegnet ved det som fremgår av patentkravene. This task is solved according to the invention by a method of the kind mentioned at the outset, which is characterized by what appears in the patent claims.
I forhold til de vanlige mykgelantinkapsler henholdvis deres fremstilling kan det med oppfinnelsen oppnås betydelige fordeler ved anvendelsen av de silikonoljer/-blandinger som benyttes på tallrike områder så som i farmasi, medisin, kosmetikk og i næringsmidler. Således er det blitt mulig å frembringe en stabil blanding av virksomme stoffer og bærersubstans, særlig en silikonoljeblanding uten å måtte ta til hjelp ytterligere tilsatsmidler, særlig emulgatorer, idet alt etter hvilken virksomme substans som skal bearbeides det kan foretas en innstilling av silikonoljens viskositet. Til dette formål står det til rådighet et bredt utvalgsområde, da silikonoljer i dag står til rådighet i viskositeter mellom 1 og 300000 mm<2>/s i farmasøytisk kvalitet. Det er derved fastslått at viskositeten for bærersubstansen ifølge oppfinnelsen avtar med økning av den virksomme mengde og tilsvarende ved en lav mengde virksom stoff bør velges relativt høy. En vesentlig fordel med oppfinnelsen må sees deri at silikonoljen selv, som virksomt stoff kan ha en egen verdi i mage-tarm-terapien, f.eks. ved flatulens (Roemheld-syndromet). Da som kjent ved forskjellige mage-tarm-preparater, særlig ved avføringsmidler på plantebasis det kan oppstå bivirkninger som flatulens og ubehag er virkningen av silikonoljer mot slike symptomer spesielt verdifull. Fremstillingsmetoden kan ved bortfall av ekstra forbedringsmidler bli vesentlig forenklet, idet forutgående blandeprosesser bortfaller og alt i alt at bare to komponenter må bringes i emulsjon. In relation to the usual soft gelatin capsules and their manufacture, the invention can achieve significant advantages in the application of the silicone oils/mixtures that are used in numerous areas such as in pharmacy, medicine, cosmetics and in foodstuffs. Thus, it has become possible to produce a stable mixture of active substances and carrier substance, in particular a silicone oil mixture, without having to use additional additives, especially emulsifiers, since depending on which active substance is to be processed, the viscosity of the silicone oil can be adjusted. For this purpose, a wide selection is available, as silicone oils are currently available in viscosities between 1 and 300,000 mm<2>/s in pharmaceutical grade. It has thereby been established that the viscosity of the carrier substance according to the invention decreases with an increase in the active amount and, correspondingly, with a low amount of active substance, a relatively high one should be chosen. A significant advantage of the invention must be seen in the fact that the silicone oil itself, as an active ingredient, can have its own value in gastrointestinal therapy, e.g. in case of flatulence (the Roemheld syndrome). As it is known with various gastrointestinal preparations, especially with plant-based laxatives, side effects such as flatulence and discomfort can occur, the effect of silicone oils against such symptoms is particularly valuable. The production method can be significantly simplified if additional improvement agents are omitted, as previous mixing processes are omitted and all in all only two components have to be brought into emulsion.
Således fremkommer spesielt hvis det som virksomt middel benyttes en planteekstrakt, f.eks. en ekstrakt sennae sicc., en dobbelfunksjon for emulgatoren, som ved siden av sin egentlige oppgave forhindrer og undertrykker bivirkninger. Til slike planteekstrakter har det vist seg spesielt hensiktsmessig med en silikonolje- viskositet på 300 mm<2>/s i samsvar med de ovenfor angitte størrelser for viskositetsvalg. Derved kan man også utnytte som fordel at senoside, dvs. det virksomme stoff i senneaekstraktet er ustabilt i vandig miljø. Av den grunn anbefales det å benytte et vannfritt hjelpemiddel. Derved er en hydrofob bærer, som for eksempel silikonolje, særlig gunstig i kombinasjon med planteekstrakter av denne art. Som ytterligere virksomt stoff kommer det imidlertid også andre planteekstrakter og substanser i betraktning, som benyttes ved mage-tarm-plager, som f.eks. ekstrakt chelidoni, ekstrakt absinthii, ekstrakt rhei, ekstrakt cynarae, ekstrakt cascarae, ekstrakt frangulae, ekstrakt aloe, ekstrakt uvae ursi eller også blandinger av disse virksomme plantestoffer. This is particularly the case if a plant extract is used as an active agent, e.g. an extract sennae sicc., a double function for the emulsifier, which, in addition to its actual task, prevents and suppresses side effects. For such plant extracts, a silicone oil viscosity of 300 mm<2>/s has proven to be particularly suitable in accordance with the above-mentioned sizes for viscosity selection. Thereby, it is also possible to take advantage of the fact that senoside, i.e. the active substance in the senna extract, is unstable in an aqueous environment. For this reason, it is recommended to use a water-free aid. Thereby, a hydrophobic carrier, such as silicone oil, is particularly beneficial in combination with plant extracts of this kind. As additional active substances, however, other plant extracts and substances are also taken into consideration, which are used for gastrointestinal complaints, such as e.g. extract chelidoni, extract absinthii, extract rhei, extract cynarae, extract cascarae, extract frangulae, extract aloe, extract uvae ursi or also mixtures of these active plant substances.
Foruten de nevnte planteekstrakter kan det som virksomme stoffer også benyttes kjemoterapeutiske stoffer. Foretrukne kjemoterapeutiske stoffer er bisacotyl og natriumspicosulfat. Derved kan den i mykgelantinkapselen opptatte blanding fordel-aktig være en suspensjon som innholder ca. 98 vekt-% silikonolje med en viskositet på 12 500 mm<2>/s og ca 2 vekt-% bisacotyl henholdsvis natriumpicosulfat. In addition to the plant extracts mentioned, chemotherapeutic substances can also be used as active substances. Preferred chemotherapeutic agents are bisacotyl and sodium spicosulfate. Thereby, the mixture contained in the soft gelatin capsule can advantageously be a suspension containing approx. 98% by weight of silicone oil with a viscosity of 12,500 mm<2>/s and approx. 2% by weight of biscotyl or sodium picosulphate.
Av fremstillings- og kostnadsgrunner men også med henblikk på administreringskrav er det rent generelt hensiktsmessig og gunstig hvis mengden av virksomme stoffer utgjør 0,2 til 75 vekt-% og bærersubstansen av silikonolje/silikonoljeblanding 99,8 til 25 vekt-%. For manufacturing and cost reasons, but also with a view to administration requirements, it is generally appropriate and beneficial if the amount of active substances amounts to 0.2 to 75% by weight and the carrier substance of silicone oil/silicone oil mixture 99.8 to 25% by weight.
Ytterligere fordeler og hensiktsmessige trekk ved oppfinnelsen fremgår av de i det følgende beskrevne utførelseseksempler. Further advantages and appropriate features of the invention can be seen from the examples described in the following.
Eksempel 1 43,3885 g silikon med en viskositet på Example 1 43.3885 g of silicone with a viscosity of
12 500 mm<2>/s (fremstilt av: "Wacker-Chemie GmbH") blandes med 0,8870 g bisacotyl (fremstilt av: "Bohringer", Ingelheim) ved 3 0 min. omrøring ved romtemperatur og med en omrøringshastighet på 500 omdreininger pr. min. Blandingen blir ført gjennom en valsemølle i ca. 15 min. Den oppnådde suspensjon er etter 2 dager fremdeles fullstendig stabil og kan innkapsles. Ved en 5 oval kapsel .med en fyllingsvekt på 250 mg gir dette et innhold på 5 mg av de kjemoterapeutiske virksomme stoffer. 12,500 mm<2>/s (manufactured by: "Wacker-Chemie GmbH") is mixed with 0.8870 g of biscotyl (manufactured by: "Bohringer", Ingelheim) at 30 min. stirring at room temperature and with a stirring speed of 500 revolutions per my. The mixture is passed through a roller mill for approx. 15 min. The obtained suspension is still completely stable after 2 days and can be encapsulated. In the case of an oval capsule with a filling weight of 250 mg, this gives a content of 5 mg of the chemotherapeutic active substances.
Eksempel 2 For en blanding av Example 2 For a mixture of
5 mg natriumpicosulfat ("Profarmaco" CH.B 170104) og 215 mg silikonolje "AK 12500" ("Wacker Chemie"; viskositet 12500 mm<2>/s; CH.B 1024 OH) 5 mg sodium picosulfate ("Profarmaco" CH.B 170104) and 215 mg silicone oil "AK 12500" ("Wacker Chemie"; viscosity 12500 mm<2>/s; CH.B 1024 OH)
til fremstilling av en for the production of a
4-oval kapsel med 220 mg fyllingsvekt 4-oval capsule with 220 mg filling weight
blir en inveining av becomes a weighting of
27,742 g silikonolje og 27.742 g silicone oil and
0,643 g (teoretisk mengde 0,645) na-picosulfat omrørt, 0.643 g (theoretical amount 0.645) Napicosulfate stirred,
homogenisert til labaratorievalsemøllen og luftet i eksikatoren. Det fremkommer en stabil, lett innkapselbar suspensjon. homogenized to the laboratory rolling mill and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Eksempel 3 For en blanding av Example 3 For a mixture of
250 mg ekstr. sennae (FLA 85.414) og 200 mg silikonolje "70047V100" ("Rhone Poulenc"; 250 mg extr. sennae (FLA 85.414) and 200 mg silicone oil "70047V100" ("Rhone Poulenc");
viskositet 100 mm<2>/s), viscosity 100 mm<2>/s),
til fremstilling av en for the production of a
7,5-oval kapsel med 450 mg fyllingsvekt 7.5-oval capsule with 450 mg filling weight
blir en innveining på becomes a reflection on
43,087 g (teoretisk mengde 43,0725) ekstr. sennae og 34,458 g silikonolje 43.087 g (theoretical amount 43.0725) extr. sennae and 34.458 g silicone oil
omrørt, homogenisert i labarotorievalsemøllen og luftet i eksikatoren. Det fremkommer en stabil, lett innkapselbar suspensjon. stirred, homogenized in the laboratory rolling mill and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Eksempel 4 For en blanding av Example 4 For a mixture of
250 mg ekstr. chelidonii 3,5% (svarende til 1,5 g av 250 mg extr. chelidonii 3.5% (equivalent to 1.5 g of
stoffet) og the substance) and
200 mg silikonolje 70047V100 ("Rhone Poulenc"; viskositet 100 mm<2>/s) 200 mg silicone oil 70047V100 ("Rhone Poulenc"; viscosity 100 mm<2>/s)
til fremstilling av en for the production of a
7,5-oval kapsel med 450 mg fyllingsvekt 7.5-oval capsule with 450 mg filling weight
blir en innveining på becomes a reflection on
40,789 g silikonolje og 40.789 g silicone oil and
50,994 g (teoretisk mengde 50,986) chelidonii omrørt, 50.994 g (theoretical amount 50.986) chelidonii stirred,
homogenisert i labaratorievalsemøllen og luftet i eksikatoren. Det fremkommer en stabil, lett innkapselbar suspensjon. homogenized in the laboratory rolling mill and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Eksempel 5 For en blanding av Example 5 For a mixture of
250 mg ekstr. absinthii sicc. (6:1 30% CH.B 0021 ECS) og 300 mg silikonolje "70047V1000" ("Rhone Poulenc"; 250 mg extr. absinthii sic. (6:1 30% CH.B 0021 ECS) and 300 mg silicone oil "70047V1000" ("Rhone Poulenc");
viskositet 1000 mm<2>/s). viscosity 1000 mm<2>/s).
til fremstilling av for the production of
10-oval kapsel med 550 mg i fyllingsvekt 10-oval capsule with 550 mg in filling weight
blir en innveining på becomes a reflection on
35,742 g silikonolje og 35.742 g silicone oil and
29,600 g (teoretisk mengde 29,786) ekstr. absinthii omrørt, homogenisert i labaratorievalsemøllen og luftet i eksikatoren. 29,600 g (theoretical amount 29,786) extr. absinthii stirred, homogenized in the laboratory roller mill and aerated in the desiccator.
Det fremkommer en stabil, lett innkapselbar suspensjon. A stable, easily encapsulated suspension is produced.
Eksempel 6 For en blanding av Example 6 For a mixture of
300 mg ekstr. rhei sicc, "DAB 7" (10% "HAD CH.B 3983 300 mg extr. rhei sicc, "DAB 7" (10% "HAD CH.B 3983
ECS") og ECS") and
200 mg silikonolje "70047V5000" ("Rhone Poulenc"; 200 mg silicone oil "70047V5000" ("Rhone Poulenc");
viskositet 5000 mm<2>/s) viscosity 5000 mm<2>/s)
til fremstilling av en for the production of a
10-oval kapsel med 500 mg i fyllingsvekt 10-oval capsule with 500 mg in filling weight
blir en innveining på becomes a reflection on
37,960 g silikonolje og 37.960 g silicone oil and
45,514 g (teoretisk mengde 45,552) ekstr. rhei omrørt, og homogenisert i labaratorievalsemøllen og luftet i eksikatoren. Det fremkomer en stabil, lett innkapselbar suspensjon. 45.514 g (theoretical amount 45.552) extr. rhei stirred, and homogenized in the laboratory roller mill and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Eksemplel 7 For en blanding av Example 7 For a mixture of
500 mg ekstr. cynarea ("FLA 85.437"; "Fa. Flachsmann") 500 mg extr. cynarea ("FLA 85.437"; "Fa. Flachsmann")
og and
500 mg silikonolje "70047V100" ("Rhone Poulenc"; 500 mg silicone oil "70047V100" ("Rhone Poulenc");
viskositet 100 mm<2>/s). viscosity 100 mm<2>/s).
til fremstilling av en for the production of a
20 avlang kapsel med 1000 mg i fyllingsvekt 20 oblong capsules with 1000 mg in filling weight
blir en innveining på becomes a reflection on
50,972 g silikonolje og 50.972 g silicone oil and
50,972 g (teoretisk mengde 50,972) ekstr. cynarae omrørt, 50.972 g (theoretical amount 50.972) extr. cynarae stirred,
homogenisert i labaratorievalsemøllen og luftet i eksikatoren. Det fremkommer en stabil suspensjon som er lett innkapselbar. homogenized in the laboratory rolling mill and aerated in the desiccator. A stable suspension is produced which is easily encapsulated.
Eksempel 8 For en blanding av Example 8 For a mixture of
100 mg ekstr. aloe "DAB 9" ("REI" 19-21% "HAD"; 100 mg extr. aloe "DAB 9" ("REI" 19-21% "HAD");
"Reisholz GmbH") og "Reisholz GmbH") and
100 mg silikonolje "70047V1000" ("Rhone Poulenc"; 100 mg silicone oil "70047V1000" ("Rhone Poulenc");
viskositet 1000 mm<2>/s) viscosity 1000 mm<2>/s)
til fremstilling av en for the production of a
4-oval kapsel med 200 mg i fyllingsvekt 4-oval capsule with 200 mg in filling weight
med en innveining på with a weighting on
9,110 g ekstr. aloe og 9.110 g extr. aloe and
9,183 g (teoretisk mengde 9,110) silikonolje omrørt, 9.183 g (theoretical amount 9.110) silicone oil stirred,
homogenisert i labaratorievalsemøllen og luftet i eksikatoren. Det fremkommer en stabil, lett innkapselbar suspensjon. homogenized in the laboratory rolling mill and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Eksempel 9 For en blanding av Example 9 For a mixture of
500 mg ekstr. uvae ursi ("Flachsmann CH.B 7D514") og 400 mg silikonolje "70047V100" ("Rhone Poulenc"; 500 mg extr. uvae ursi ("Flachsmann CH.B 7D514") and 400 mg silicone oil "70047V100" ("Rhone Poulenc");
viskositet 100 mm<2>/s) viscosity 100 mm<2>/s)
til fremstilling av en for the production of a
16 avlang kapsel med 900 mg i fyllingsvekt 16 oblong capsules with 900 mg in filling weight
blir en innveining på becomes a reflection on
37,171 g silikonolje og 37.171 g silicone oil and
46,430 g (teoretisk mengde 46,464) ekstr. uvae ursi omrørt, homogenisert i labaratorievalsemøllen, og luftet i eksikatoren. Det fremkommer en stabil, lett innkapselbar suspensjon. 46.430 g (theoretical amount 46.464) extr. uvae ursi stirred, homogenized in the laboratory roller mill, and aerated in the desiccator. A stable, easily encapsulated suspension is produced.
Claims (10)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3818022A DE3818022C2 (en) | 1988-05-24 | 1988-05-24 | Soft gelatin capsule |
| EP90250146A EP0464274B1 (en) | 1988-05-24 | 1990-06-06 | Soft gelatin capsule |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO892077D0 NO892077D0 (en) | 1989-05-24 |
| NO892077L NO892077L (en) | 1989-11-27 |
| NO178175B true NO178175B (en) | 1995-10-30 |
| NO178175C NO178175C (en) | 1996-02-07 |
Family
ID=40139159
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO892077A NO178175C (en) | 1988-05-24 | 1989-05-24 | Process for preparing a soft gelatin capsule |
| NO91912177A NO912177L (en) | 1988-05-24 | 1991-06-06 | A soft gelatin capsule. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO91912177A NO912177L (en) | 1988-05-24 | 1991-06-06 | A soft gelatin capsule. |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0343575B1 (en) |
| AT (1) | ATE120088T1 (en) |
| DE (2) | DE3818022C2 (en) |
| DK (1) | DK251089A (en) |
| ES (1) | ES2034494T3 (en) |
| FI (2) | FI101935B1 (en) |
| IE (1) | IE63327B1 (en) |
| NO (2) | NO178175C (en) |
| PT (1) | PT90640B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3818022C2 (en) * | 1988-05-24 | 1994-04-28 | Guenter Stephan | Soft gelatin capsule |
| CH683594A5 (en) * | 1991-01-24 | 1994-04-15 | Flachsmann Ag Emil | A process for the preparation of a composition containing plant extract which is particularly suitable for the encapsulation into a rigid covering material. |
| DE4219330C2 (en) * | 1992-06-10 | 1994-06-09 | Guenter Stephan | Water soluble instant tea product |
| AU6251094A (en) * | 1993-02-26 | 1994-09-14 | Procter & Gamble Company, The | Bisacodyl dosage form |
| GB2281697A (en) * | 1993-09-14 | 1995-03-15 | Euro Celtique Sa | Laxative compositions in capsules |
| AU7961094A (en) * | 1993-10-19 | 1995-05-08 | Procter & Gamble Company, The | Picosulphate dosage form |
| GB2290965A (en) * | 1994-07-11 | 1996-01-17 | Therapicon Srl | Multiple layer capsules for drugs |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3202578A (en) * | 1957-09-27 | 1965-08-24 | Elder Paul B Co | Polymeric laxative composition and method of using same |
| FR5549M (en) * | 1966-04-14 | 1967-11-20 | ||
| FR2077790A1 (en) * | 1970-02-13 | 1971-11-05 | Broutin Heliane | Anti-rheumatism medicament - contg butylsalicylamine and ethyl salicylamide |
| DE2614864C3 (en) * | 1976-04-06 | 1979-11-29 | Schwabe, Willmar, Dr., 7500 Karlsruhe | Process for the production of medicinal preparations containing digoxin in soft gelatin capsules for oral administration |
| IT1090703B (en) * | 1976-12-03 | 1985-06-26 | Scherer Ltd R P | IMPROVEMENT IN USEFUL COMPOSITIONS SUCH AS DRUG VEHICLES |
| DE2712161C2 (en) * | 1977-03-19 | 1983-01-05 | Blendax-Werke R. Schneider Gmbh & Co, 6500 Mainz | Dental and oral care products |
| FR2390953A1 (en) * | 1977-05-20 | 1978-12-15 | Grimberg Georges | Medicaments for intestinal disorders - contain activated charcoal and a substance which delays release of the charcoal |
| FR2605223B1 (en) * | 1986-10-20 | 1989-09-22 | Pf Medicament | STABLE THERAPEUTIC COMPOSITIONS BASED ON HYDROPHOBIC VEGETABLE OIL AND PROCESS FOR PREPARING THE SAME |
| HU203285B (en) * | 1988-02-01 | 1991-07-29 | Egyt Gyogyszervegyeszeti Gyar | Method for producing transdermal preparation containing vegetable extract |
| DE3818022C2 (en) * | 1988-05-24 | 1994-04-28 | Guenter Stephan | Soft gelatin capsule |
-
1988
- 1988-05-24 DE DE3818022A patent/DE3818022C2/en not_active Expired - Fee Related
-
1989
- 1989-05-23 EP EP89109215A patent/EP0343575B1/en not_active Expired - Lifetime
- 1989-05-23 ES ES198989109215T patent/ES2034494T3/en not_active Expired - Lifetime
- 1989-05-23 IE IE166389A patent/IE63327B1/en not_active IP Right Cessation
- 1989-05-23 PT PT90640A patent/PT90640B/en not_active IP Right Cessation
- 1989-05-24 DK DK251089A patent/DK251089A/en not_active Application Discontinuation
- 1989-05-24 NO NO892077A patent/NO178175C/en not_active IP Right Cessation
- 1989-05-24 FI FI892524A patent/FI101935B1/en not_active IP Right Cessation
-
1990
- 1990-06-06 EP EP90250146A patent/EP0464274B1/en not_active Expired - Lifetime
- 1990-06-06 AT AT90250146T patent/ATE120088T1/en not_active IP Right Cessation
- 1990-06-06 DE DE59008770T patent/DE59008770D1/en not_active Expired - Fee Related
-
1991
- 1991-06-04 FI FI912690A patent/FI912690A/en not_active Application Discontinuation
- 1991-06-06 NO NO91912177A patent/NO912177L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE120088T1 (en) | 1995-04-15 |
| NO892077D0 (en) | 1989-05-24 |
| DK251089D0 (en) | 1989-05-24 |
| IE891663L (en) | 1989-11-24 |
| EP0343575A1 (en) | 1989-11-29 |
| NO892077L (en) | 1989-11-27 |
| DE3818022C1 (en) | 1989-10-19 |
| EP0464274A1 (en) | 1992-01-08 |
| EP0343575B1 (en) | 1992-08-26 |
| DE3818022C2 (en) | 1994-04-28 |
| NO912177D0 (en) | 1991-06-06 |
| FI101935B (en) | 1998-09-30 |
| FI892524A (en) | 1989-11-25 |
| NO912177L (en) | 1991-12-09 |
| EP0464274B1 (en) | 1995-03-22 |
| ES2034494T3 (en) | 1993-04-01 |
| NO178175C (en) | 1996-02-07 |
| FI912690A (en) | 1991-12-07 |
| FI912690A0 (en) | 1991-06-04 |
| DK251089A (en) | 1989-11-25 |
| FI892524A0 (en) | 1989-05-24 |
| PT90640A (en) | 1989-11-30 |
| IE63327B1 (en) | 1995-04-05 |
| FI101935B1 (en) | 1998-09-30 |
| DE59008770D1 (en) | 1995-04-27 |
| PT90640B (en) | 1994-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4325942A (en) | Ubidecarenone compositions having enhanced absorption properties | |
| CH652307A5 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL USE. | |
| US6617356B2 (en) | Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements | |
| JPH0474339B2 (en) | ||
| CN109528649A (en) | A kind of terpenes pharmaceutical composition self-emulsifiable oral preparation and preparation method, application | |
| WO1984002271A1 (en) | Readily-absorpable fatty acid emulsions | |
| JP2008536879A (en) | Drug or nutrition combination preparation and preparation, method for improving absorption by internal use, and application method thereof | |
| NO178175B (en) | Process for preparing a soft gelatin capsule | |
| JPS6230965B2 (en) | ||
| CA1340836C (en) | Mixed compositions for treating hypercholesterolemia | |
| JP3996691B2 (en) | Emulsified powder and method for producing the same | |
| EP0198769A2 (en) | Floating sustained release therapeutic compositions | |
| JPH01249716A (en) | Fatty emulsion of fine particle | |
| AU710479B2 (en) | Antiglucocorticoid medicament | |
| Pinheiro et al. | Amphotericin B-loaded emulgel: effect of chemical enhancers on the release profile and antileishmanial activity in vitro | |
| CN106377566B (en) | Castor oil cyclodextrin liquid dispersant and preparation method thereof | |
| CN109939071A (en) | A kind of rhodioside-vitamin E two-phase proliposome and its preparation method and application | |
| JPS58163429A (en) | Emulsifier composition | |
| CN104095812B (en) | The preparation method of the emulsifiable oily injection containing Avermectins medicine | |
| EP0073006B1 (en) | Medicinal composition and method of making same | |
| Lokhande | Recent Trends in Multiple Emulsion-A Comprehensive Review | |
| CN113350374B (en) | Preparation method of calcium phosphate and vitamin D composite microcapsule | |
| WO2023053077A1 (en) | A nano emulsified phyto-drug for transdermal treatment of diabetes | |
| RU2112532C1 (en) | Medicinal and prophylactic preparation "eucophyt" | |
| JPS58163430A (en) | Emulsifier composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN NOVEMBER 2001 |